A detailed history of Second Half Financial Partners, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Second Half Financial Partners, LLC holds 2,402 shares of ABBV stock, worth $430,438. This represents 0.29% of its overall portfolio holdings.

Number of Shares
2,402
Previous 2,414 0.5%
Holding current value
$430,438
Previous $414,000 14.49%
% of portfolio
0.29%
Previous 0.39%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$163.84 - $199.33 $1,966 - $2,391
-12 Reduced 0.5%
2,402 $474,000
Q2 2024

Aug 08, 2024

BUY
$154.79 - $180.76 $4,953 - $5,784
32 Added 1.34%
2,414 $414,000
Q1 2024

May 09, 2024

BUY
$159.82 - $182.1 $16,301 - $18,574
102 Added 4.47%
2,382 $433,000
Q4 2023

Feb 07, 2024

BUY
$137.6 - $154.97 $2,476 - $2,789
18 Added 0.8%
2,280 $353,000
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $836,139 - $967,954
-6,259 Reduced 73.45%
2,262 $337,000
Q3 2023

Nov 03, 2023

SELL
$133.59 - $154.65 $1.71 Million - $1.98 Million
-12,802 Reduced 60.04%
8,521 $1.27 Million
Q2 2023

Aug 07, 2023

SELL
$132.51 - $164.9 $375,003 - $466,667
-2,830 Reduced 11.72%
21,323 $2.87 Million
Q1 2023

May 11, 2023

SELL
$144.61 - $166.54 $22,848 - $26,313
-158 Reduced 0.65%
24,153 $3.85 Million
Q4 2022

Feb 13, 2023

SELL
$138.31 - $165.87 $5,947 - $7,132
-43 Reduced 0.18%
24,311 $3.93 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $2.01 Million - $2.3 Million
-14,965 Reduced 38.06%
24,354 $3.27 Million
Q1 2022

Sep 20, 2022

BUY
$131.98 - $163.75 $5.19 Million - $6.44 Million
39,319 New
39,319 $4.26 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $317B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Second Half Financial Partners, LLC Portfolio

Follow Second Half Financial Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Second Half Financial Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Second Half Financial Partners, LLC with notifications on news.